University of Kansas

University of Kansas

University of Kansas

Overview
Date Founded

1865

Headquarters

1502 Iowa Street,Lawrence, KS 66045-7576

Industries

Private Equity & Venture Capital

Company Description

The University of Kansas (KU) is a public research university and the largest university in the State of Kansas. KU campuses are located in Lawrence, Wichita, Overland Park, Salina, and Kansas City, Kansas, with the main campus located in Lawrence on Mount Oread, the highest location in Lawrence. The University was opened in 1866, under a charter granted by the Kansas Legislature in 1864.

Contact Data
Trying to get in touch with decision makers at University of Kansas? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees
Board of Directors

Co-Owner at Long John Silver's LLC

General Partner at Sofinnova Investments, Inc.

Chief Executive Officer & Co-Founder at Digital Evolution Group LLC

Distinguished Alumni
Linda Zarda Cook is now Chief Executive Officer & Director at Harbour Energy Plc
David G. Booth is now Founder & Executive Chairman at Dimensional Fund Advisors LP
Peter Alex Mallouk is now President & Chief Investment Officer at Creative Planning, Inc.
Paths to University of Kansas
Potential Connections via
Relationship Science
You
University of Kansas
Advisors & Consultants
Advisor

Partner, Grants Administration & Research Compliance at Baker Tilly US LLP

Advisor

Chairman at Grenzebach Glier & Associates, Inc.

Consultant

Senior Vice President at Grenzebach Glier & Associates, Inc.

Clients

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Non-Profit Donations & Grants Received
Investments
Details Hidden

AstrumU, Inc. designs and develops machine learning solutions to help students find careers. The firm offers AstrumU platform. The company was founded by Adam Wray in 2017 and is headquartered in Kirkland, WA.

Details Hidden

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Details Hidden

Vasogenix Pharmaceuticals, Inc. develops cardiology drug products for acute treatment of life threatening ischemia associated with myocardial infarction and the chronic treatment of congestive heart failure. The company was founded in 2001 and is headquartered in Lenexa, KS.

Suppliers
ImpediMed Ltd. Industrial Machinery & Manufacturing | Pinkenba, Australia

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. It operates through the Medical, and Test and Measurement segments. The Medical segment supplies non-invasive medical technology products and services to measure, monitor, and manage tissue composition and fluid status using bioimpedance spectroscopy. The Test and Measurement segment offers power precision testing and measuring equipment. The company was founded by Melvyn John Bridges and Lucille Mayse Bridges on September 27, 1999 and is headquartered in Pinkenba, Australia.

Quanterix Corp. Biotechnology | Lexington, MA

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Awards & Honors
Rank #188
2010
The Chronicle of Philanthropy - Philanthropy 400
Rank #173
2009
The Chronicle of Philanthropy - Philanthropy 400
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by University of Kansas. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of University of Kansas's profile does not indicate a business or promotional relationship of any kind between RelSci and University of Kansas.